JP7100210B2 - 複素環化合物、その製造方法および用途 - Google Patents

複素環化合物、その製造方法および用途 Download PDF

Info

Publication number
JP7100210B2
JP7100210B2 JP2021569009A JP2021569009A JP7100210B2 JP 7100210 B2 JP7100210 B2 JP 7100210B2 JP 2021569009 A JP2021569009 A JP 2021569009A JP 2021569009 A JP2021569009 A JP 2021569009A JP 7100210 B2 JP7100210 B2 JP 7100210B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
mmol
formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525247A (ja
Inventor
シン ダイ
ヤオリン ワン
ユエハン チアン
ヤンチン リュー
ジー シ
ジェンウ ワン
リアンシャン タオ
ジシン ハン
ハオタオ ニュウ
ジファン ウェン
Original Assignee
インベンティスバイオ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンティスバイオ カンパニー リミテッド filed Critical インベンティスバイオ カンパニー リミテッド
Publication of JP2022525247A publication Critical patent/JP2022525247A/ja
Priority to JP2022105508A priority Critical patent/JP7679338B2/ja
Application granted granted Critical
Publication of JP7100210B2 publication Critical patent/JP7100210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021569009A 2019-05-21 2020-05-20 複素環化合物、その製造方法および用途 Active JP7100210B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105508A JP7679338B2 (ja) 2019-05-21 2022-06-30 複素環化合物、その製造方法および用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019087772 2019-05-21
CNPCT/CN2019/087772 2019-05-21
CNPCT/CN2019/095947 2019-07-15
CN2019095947 2019-07-15
CNPCT/CN2019/123223 2019-12-05
CN2019123223 2019-12-05
PCT/CN2020/091274 WO2020233592A1 (en) 2019-05-21 2020-05-20 Heterocyclic compounds, preparation methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105508A Division JP7679338B2 (ja) 2019-05-21 2022-06-30 複素環化合物、その製造方法および用途

Publications (2)

Publication Number Publication Date
JP2022525247A JP2022525247A (ja) 2022-05-11
JP7100210B2 true JP7100210B2 (ja) 2022-07-12

Family

ID=73459463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569009A Active JP7100210B2 (ja) 2019-05-21 2020-05-20 複素環化合物、その製造方法および用途
JP2022105508A Active JP7679338B2 (ja) 2019-05-21 2022-06-30 複素環化合物、その製造方法および用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105508A Active JP7679338B2 (ja) 2019-05-21 2022-06-30 複素環化合物、その製造方法および用途

Country Status (12)

Country Link
US (2) US11091481B2 (https=)
EP (1) EP3972967A4 (https=)
JP (2) JP7100210B2 (https=)
KR (1) KR102944305B1 (https=)
CN (3) CN118359609A (https=)
AU (1) AU2020279287B2 (https=)
BR (1) BR112021023136A2 (https=)
CA (1) CA3139348A1 (https=)
IL (1) IL288104B1 (https=)
MX (1) MX2021014096A (https=)
WO (1) WO2020233592A1 (https=)
ZA (1) ZA202110422B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506308A (ja) * 2019-12-18 2023-02-15 インベンティスバイオ カンパニー リミテッド 複素環化合物およびその製造方法と使用

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932633B2 (en) 2018-05-07 2024-03-19 Mirati Therapeutics, Inc. KRas G12C inhibitors
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
WO2020055761A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
WO2020085504A1 (ja) 2018-10-26 2020-04-30 大鵬薬品工業株式会社 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法
CN113164418A (zh) 2018-12-05 2021-07-23 米拉蒂治疗股份有限公司 组合疗法
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
CN114671866A (zh) * 2020-12-25 2022-06-28 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN113105448A (zh) * 2020-01-13 2021-07-13 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN115175908B (zh) * 2020-01-13 2024-07-23 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
CN112159405B (zh) * 2020-02-04 2021-09-14 广州必贝特医药技术有限公司 吡啶并嘧啶酮类化合物及其应用
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2021175199A1 (zh) * 2020-03-02 2021-09-10 上海喆邺生物科技有限公司 一类芳香杂环类化合物及其在药物中的应用
WO2021249563A1 (zh) * 2020-06-12 2021-12-16 苏州泽璟生物制药股份有限公司 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
WO2022037560A1 (zh) * 2020-08-21 2022-02-24 广东东阳光药业有限公司 嘧啶酮衍生物及其在药物中的应用
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
WO2022056307A1 (en) 2020-09-11 2022-03-17 Mirati Therapeutics, Inc. Crystalline forms of a kras g12c inhibitor
AU2021347232A1 (en) 2020-09-23 2023-04-27 Erasca, Inc. Tricyclic pyridones and pyrimidones
WO2022111521A1 (zh) * 2020-11-24 2022-06-02 杭州多域生物技术有限公司 一种芳香化合物、其制备方法及应用
HRP20251311T1 (hr) * 2020-11-26 2026-02-27 Shanghai Hansoh Biomedical Co., Ltd. Sol i kristalni oblik heterocikličkog derivata koji sadrži dušik, metoda njihove pripreme i njihova primjena
WO2022132200A1 (en) 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022133345A1 (en) 2020-12-18 2022-06-23 Erasca, Inc. Tricyclic pyridones and pyrimidones
CN116249703A (zh) * 2020-12-21 2023-06-09 上海和誉生物医药科技有限公司 一种大环k-ras g12c抑制剂，其制备方法和用途
US20240189313A1 (en) * 2021-03-11 2024-06-13 InventisBio Co., Ltd. Solid dispersions
US20240293558A1 (en) 2021-06-16 2024-09-05 Erasca, Inc. Kras inhibitor conjugates
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
US20250177406A1 (en) 2022-03-31 2025-06-05 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
WO2024081674A1 (en) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Combination therapies for the treatment of cancer
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
JPWO2024209717A1 (https=) 2023-04-06 2024-10-10
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
TW202529768A (zh) 2023-09-29 2025-08-01 大陸商德昇濟醫藥（無錫）有限公司 癌症治療的療法
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025242126A1 (zh) * 2024-05-22 2025-11-27 上海正大天晴医药科技开发有限公司 一种药物组合及其应用
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) * 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
PT3735299T (pt) 2018-11-09 2024-11-25 Hoffmann La Roche Compostos de anéis fundidos
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN110256421A (zh) 2019-06-26 2019-09-20 微境生物医药科技(上海)有限公司 Kras-g12c抑制剂
CN111377918B (zh) 2019-11-29 2021-03-02 苏州信诺维医药科技有限公司 一种kras抑制剂化合物
CN111205286B (zh) 2020-01-13 2022-12-13 中科苏州药物研究院 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119183A2 (en) 2016-12-22 2018-06-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2018217651A1 (en) 2017-05-22 2018-11-29 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019051291A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023506308A (ja) * 2019-12-18 2023-02-15 インベンティスバイオ カンパニー リミテッド 複素環化合物およびその製造方法と使用
JP7710449B2 (ja) 2019-12-18 2025-07-18 インベンティスバイオ カンパニー リミテッド 複素環化合物およびその製造方法と使用

Also Published As

Publication number Publication date
KR20220010542A (ko) 2022-01-25
BR112021023136A2 (pt) 2022-01-04
ZA202110422B (en) 2024-03-27
JP2022130631A (ja) 2022-09-06
IL288104A (en) 2022-01-01
US20210355125A1 (en) 2021-11-18
WO2020233592A1 (en) 2020-11-26
IL288104B1 (en) 2026-04-01
CN114437065A (zh) 2022-05-06
MX2021014096A (es) 2022-02-11
CA3139348A1 (en) 2020-11-26
EP3972967A4 (en) 2023-07-12
JP2022525247A (ja) 2022-05-11
US11091481B2 (en) 2021-08-17
CN112585129B (zh) 2022-03-01
AU2020279287A1 (en) 2021-12-16
KR102944305B1 (ko) 2026-03-25
US12110289B2 (en) 2024-10-08
CN118359609A (zh) 2024-07-19
CN112585129A (zh) 2021-03-30
AU2020279287B2 (en) 2025-11-27
JP7679338B2 (ja) 2025-05-19
EP3972967A1 (en) 2022-03-30
US20210198255A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP7100210B2 (ja) 複素環化合物、その製造方法および用途
JP7644023B2 (ja) ホスファチジルイノシトール３－キナーゼ阻害剤
EP3322711B1 (en) Hpk1 inhibitors and methods of using same
KR102816365B1 (ko) 피라진 화합물 및 이의 용도
TW202509040A (zh) 三環類化合物及其用途
AU2022200478B2 (en) Inhibitors of KEAP1-Nrf2 protein-protein interaction
CN118745176A (zh) 含氮杂环类衍生物调节剂、其制备方法和应用
CN116390917B (zh) Mrgx2拮抗剂
CN113348170B (zh) 联苯类衍生物抑制剂、其制备方法和应用
CN113272305A (zh) 吲哚ahr抑制剂及其用途
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
CN104854108A (zh) 作为pi3k抑制剂的吡咯并三嗪酮
WO2020188467A1 (zh) 作为激酶抑制剂的稠合三环化合物
TW202140488A (zh) 雜芳基雜環化合物及其用途
CN116490188A (zh) 含氮杂环类衍生物的盐、晶型及其制备方法和应用
JP7551607B2 (ja) アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
RU2828748C2 (ru) Гетероциклические соединения, способы их получения и применения
HK40041256A (en) Heterocyclic compounds, preparation methods and uses thereof
HK40041256B (en) Heterocyclic compounds, preparation methods and uses thereof
HK40121672A (zh) 杂芳基杂环化合物及其用途
HK40074266B (zh) 杂芳基杂环化合物及其用途
HK40058262B (zh) 含氮杂环类衍生物调节剂、其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220107

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220107

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7100210

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250